Rituximab biosimilar - Prestige BioPharma

Drug Profile

Rituximab biosimilar - Prestige BioPharma

Alternative Names: PBP 1506; Rituxan biosimilar - Prestige BioPharma

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prestige BioPharma
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Arthritis; Non-Hodgkin's lymphoma

Most Recent Events

  • 18 Jan 2017 Early research in Arthritis in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)
  • 18 Jan 2017 Early research in Non-Hodgkin's lymphoma in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top